Unilever PLC Sponsored ADR (UL.US) is considering a potential $4 billion acquisition of the health supplement giant Thorne as part of its health transformation strategy.

According to sources familiar with the matter, the British-Dutch consumer goods giant Unilever PLC Sponsored ADR (UL.US) is considering acquiring the American healthcare product manufacturer Thorne, with the transaction valued at up to $4 billion. Thorne, listed for sale by the private equity firm L Catterton, is one of many bidders, with Unilever PLC Sponsored ADR being one of them. Sources revealed that the consumer health products company Haleon has also made a bid to acquire Thorne. The deal is still in the early stages, with no final decision made yet, and both Unilever PLC Sponsored ADR and L Catterton have declined to comment. Founded in 1984 and based in South Carolina, Thorne is a leading scientific-driven dietary supplement brand in the U.S., offering products such as magnesium, omega-3, and other nutritional supplements. The company is highly recommended by healthcare professionals and provides innovative technology tools, including the AI health advisor Taia. In August 2023, L Catterton privatized Thorne at a price of $10.20 per share, totaling $680 million. At that time, Thorne had just been listed on NASDAQ in 2021 for two years. If the deal goes through at a valuation of $4 billion, L Catterton will receive nearly 5 times the return on investment in just three years. Thorne has seen rapid growth in recent years, with revenue doubling from $229 million in 2022 to over $500 million by 2025. Reports suggest that Thorne's annual revenue for this year is expected to reach $650 million. CEO Colin Watts stated that millennials and Generation Z are spending more on health than the baby boomer generation, reshaping the landscape of the healthcare market, with Thorne being a major beneficiary of this generational shift. The strategic logic of Unilever PLC Sponsored ADR: from "slimming down" to "focusing" This potential acquisition is the latest move by Unilever PLC Sponsored ADR's CEO Fernando Fernandez to drive the group's strategic transformation since taking office. Since 2025, Unilever PLC Sponsored ADR has been undergoing a profound strategic reshaping - selling its food business, divesting its ice cream business, and shifting its focus to high-growth areas such as beauty and health, and personal care. In April 2026, Unilever PLC Sponsored ADR acquired the American gummy supplement brand Grns for approximately $1.2 billion. Grns achieved an annualized revenue breakthrough of $300 million in 2025, with daily shipments of approximately 10 million gummies. Prior to this, the company had already acquired liquid supplement brand Liquid IV, hair health brand Nutrafol, and vitamin gummy brands Olly Nutrition and SmartyPants. Unilever PLC Sponsored ADR's healthcare division achieved double-digit sales growth in 2025. The logic behind these acquisitions is clear: after divesting its food business to McCormick & Company, Incorporated for approximately $66 billion, Unilever PLC Sponsored ADR is rapidly building a brand portfolio focused on "science-driven beauty and health." Thorne's clinical professional positioning, high repeat purchase rates, and strong presence in the U.S. market complement Unilever PLC Sponsored ADR's existing mass-market health brands (such as Olly and Grns) - the former targeting professional channels and high-end users, and the latter catering to the general consumer market. However, Unilever PLC Sponsored ADR's acquisition history has not been without controversy. Following the acquisition of brands like Dollar Shave Club and Graze, these brands faced operational difficulties after being integrated into the group. Maintaining Thorne's brand independence and rapid growth within a large corporate system will be a challenge for management. There is room for negotiation on the valuation side. The $4 billion valuation corresponds to a market-to-sales ratio of about 6.2 times Thorne's estimated revenue of $650 million in 2026. In comparison, when Unilever PLC Sponsored ADR acquired Grns in April, the valuation of approximately $1.2 billion corresponded to a market-to-sales ratio of about 4 times based on its 2025 revenue of $300 million. The premium on Thorne reflects its brand barriers in professional medical channels and higher growth certainty, but also implies greater integration risk.